Abstract
The American College of Cardiology Foundation, along with key specialty and subspecialty societies, conducted an appropriate use review of common clinical scenarios where cardiac computed tomography (CCT) is frequently considered. The present document is an update to the original CCT/cardiac magnetic resonance appropriateness criteria published in 2006, written to reflect changes in test utilization, to incorporate new clinical data, and to clarify CCT use where omissions or lack of clarity existed in the original criteria. 1 The indications for this review were drawn from common applications or anticipated uses, as well as from current clinical practice guidelines. Ninety-three clinical scenarios were developed by a writing group and scored by a separate technical panel on a scale of 1 to 9 to designate appropriate use, inappropriate use, or uncertain use.
In general, use of CCT angiography for diagnosis and risk assessment in patients with low or intermediate risk or pretest probability for coronary artery disease was viewed favorably, whereas testing in high-risk patients, routine repeat testing, and general screening in certain clinical scenarios were viewed less favorably. Use of noncontrast computed tomography for calcium scoring was rated as appropriate within intermediate-and selected low-risk patients. Appropriate applications of CCT are also within the category of cardiac structural and functional evaluation. It is anticipated that these results will have an impact on physician decision making, performance, and reimbursement policy, and that they will help guide future research.
Preface
In an effort to respond to the need for the rational use of imaging services in the delivery of high-quality care, the ACCF has undertaken a process to determine the appropriate use of cardiovascular imaging for selected patient indications.
Appropriate use criteria publications reflect an ongoing effort by the ACCF to critically and systematically create, review, and categorize clinical situations where diagnostic tests and procedures are utilized by physicians caring for patients with cardiovascular diseases. The process is based on current understanding of the technical capabilities of the imaging modalities examined. Although not intended to be entirely comprehensive, the indications are meant to identify common scenarios encompassing the majority of contemporary practice. Given the breadth of information they convey, the indications do not directly correspond to the ninth revision of the International Classification of Diseases-9 (ICD-9) system as these codes do not include clinical information, such as symptom status.
The ACCF believes that careful blending of a broad range of clinical experiences and available evidence-based informa-tion will help guide a more efficient and equitable allocation of healthcare resources in cardiovascular imaging. The ultimate objective of appropriate use criteria is to improve patient care and health outcomes in a cost-effective manner but is not intended to ignore ambiguity and nuance intrinsic to clinical decision making. Local parameters, such as the availability or quality of equipment or personnel, may influence the selection of appropriate imaging procedures. Appropriate use criteria thus should not be considered substitutes for sound clinical judgment and practice experience.
The ACCF appropriate use criteria process itself is also evolving. In the current iteration, technical panel members were asked to rate indications for CCT in a manner independent and irrespective of the prior published ACCF ratings for CCT and CMR 1 as well as the prior ACCF ratings for similar diagnostic stress imaging modalities such as cardiac radionuclide imaging 2 or stress echocardiography 3 (see Appendix A for the definitions of terms used throughout the indication set). Given the iterative nature of the process, readers are counseled not to compare too closely individual appropriate use ratings among modalities rated at different times over the past 2 years. A comparative evaluation of the appropriate use of multiple imaging techniques is currently being undertaken to assess the relative strengths of each modality for various clinical scenarios.
We are grateful to the technical panel, a professional group with a wide range of skills and insights, for their thoughtful and thorough deliberation of the merits of CCT for various indications. In addition to our thanks to the technical panel for their dedicated work and review, we would like to offer special thanks to the many individuals who provided a careful review of the draft indications; to Peggy Christiansen, the ACCF librarian for her comprehensive literature searches; to Lindsey Law, Starr Webb, and Joseph M. Allen, who continually drove the process forward; and to Allen J. Taylor, MD, the chair of the writing committee for his dedication, insight, and leadership.
Introduction
This report addresses the appropriate use of CCT. Improvements in cardiovascular imaging technology and their application, coupled with increasing therapeutic options for cardiovascular disease, have led to an increase in cardiovascular imaging. At the same time, the armamentarium of noninvasive diagnostic tools has expanded with innovations in new contrast agents, molecular radionuclide imaging, perfusion echocardiography, computed tomography for coronary angiography and calcium scoring, and magnetic resonance imaging for myocardial structure and viability. As the field of CCT continues to advance along with other imaging modalities, the healthcare community needs to understand how to best incorporate this technology into daily clinical care.
All prior appropriate use criteria publications from the ACCF and collaborating organizations have reflected an ongoing effort to critically and systematically create, review, and categorize the appropriate use of certain cardiovascular diagnostic tests. The ACCF recognizes the importance of revising these criteria in a timely manner in order to provide the cardiovascular community with the most accurate indications. The present document is the second update to an existing appropriate use criteria document, the "ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR Appropriateness Criteria for Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging," published in 2006. 1 Clinicians, payers, and patients are interested in the specific benefits of CCT. Of importance, inappropriate use of CCT may be potentially harmful to patients and generate unwarranted costs to the healthcare system, whereas appropriate procedures should likely improve patients' clinical outcomes. This is a critical shift because the intent is for the potential benefits and risks of the treatment to be explicitly considered, rather than the potential usefulness of a diagnostic test as a prelude to further treatment. This document presents the results of this effort, but it is critical to understand the background and scope of this document before interpreting the rating tables.
Methods
The indications included in this review are purposefully broad, and they comprise a wide array of cardiovascular signs and symptoms as well as clinical judgment as to the likelihood of cardiovascular findings.
Further description of the methods used for ranking of the selected clinical indications is outlined in Appendix B and is also found more generally in a previous publication, "ACCF Proposed Method for Evaluating the Appropriateness of Cardiovascular Imaging". 4 Briefly, this process combines evidence-based medicine and practice experience by engaging a technical panel in a modified Delphi exercise. Because the original CCT/CMR criteria document and methods paper was published, several important processes have been put in place to further enhance this process. They include convening a formal writing committee with diverse expertise in imaging, circulating the indications for external review prior to rating by the technical panel, ensuring appropriate balance of the technical panel, a standardized rating package, and creating formal roles for facilitating panel interaction at the face-to-face meeting.
The panel first rated indications independently. In rating these criteria, the Cardiac Computed Tomography Appropriate Use Criteria Technical Panel was asked to assess whether the use of the test for each indication is appropriate, uncertain, or inappropriate as defined in the following text.
An appropriate imaging study is one in which the expected incremental information, combined with clinical judgment, exceeds the expected negative consequences* by a sufficiently wide margin for a specific indication that the procedure is generally considered acceptable care and a reasonable approach for the indication.
The technical panel scores each indication as follows:
Appropriate test for specific indication (test is generally acceptable and is a reasonable approach for the indication).
*Negative consequences include the risks of the procedure (radiation or contrast exposure) and the downstream impact of poor test performance such as delay in diagnosis (false negatives) or inappropriate diagnosis (false positives).
Score 4 to 6
Uncertain for specific indication (test may be generally acceptable and may be a reasonable approach for the indication). (Uncertainty also implies that more research and/or patient information is needed to classify the indication definitively.)
Score 1 to 3
Inappropriate test for specific indication (test is not generally acceptable and is not a reasonable approach for the indication).
Then the panel was convened for a face-to-face meeting for discussion of each indication. At this meeting, panel members were provided with their scores and a blinded summary of their peers' scores. After the consensus meeting, panel members were then asked to independently provide their final scores for each indication. Following the second round ratings, a supplemental rating process was conducted for a revised set of criteria for preoperative testing (31 to 38) and the clinical scenario of prior revascularization (40 to 41). Although these categories had been considered within the original 2 rounds of rating, the clinical scenarios were rewritten to more closely mirror prior documents, and the balloting was repeated.
The contributors acknowledge that the division of these scores into 3 categories of appropriate use is somewhat arbitrary and that the numeric designations should be viewed as a continuum. The contributors also recognize diversity in clinical opinion for particular clinical scenarios. Scores in the intermediate level of appropriate use should therefore be labeled uncertain, as critical patient or research data may be lacking or discordant. This designation should be a prompt to the field to carry out definitive research, whenever possible. It is anticipated that the appropriate use criteria reports will require updates as further data are generated and information from the implementation of the criteria is accumulated.
To avoid bias in the scoring process, the technical panel deliberately was not comprised solely of specialists in the particular procedure under evaluation. Specialists, while offering important clinical and technical insights, might have a natural tendency to rate the indications within their specialty as more appropriate than nonspecialists. In addition, care was taken in providing objective, nonbiased information, including guidelines and key references, to the technical panel. Panel members were not provided explicit cost information to help determine their appropriate use ratings, but they were asked to implicitly consider cost as an additional factor in their evaluation of appropriate use.
The level of agreement among panel members, as defined by RAND, 5 was analyzed for each indication based on the BIOMED rule for a panel of 14 to 16 (a simplified RAND method for determining disagreement). Per the BIOMED definition, agreement was defined as an indication where 4 or fewer panel members ratings fell outside the 3-point region containing the median score. Disagreement was defined as a situation where at least 5 panel members ratings fell in both the appropriate and the inappropriate categories. Because the panel had 17 representatives, which exceeded the 16 addressed in this rule, an additional level of agreement analysis as described by RAND was performed that examines the interpercentile range (IPR) compared with the interpercentile range adjusted for symmetry (IPRAS). This information was used by the moderator to guide the panel's discussion by highlighting areas of differences among the panel members. There was also a third category for indications that were not classified in either the agreement or disagreement categories. Any indication having disagreement was categorized as uncertain regardless of the final median score. Indications that met neither definition for agreement or disagreement are in a third, unlabeled, category.
General Assumptions
All indications were considered with the following important assumptions for CCT: 1. CCT is performed in accordance with best practice standards as delineated in the imaging guidelines of the Society of Cardiovascular Computed Tomography, 6,7 by competent 8 and appropriately credentialed physicians. This includes the optimization of the scan protocol to limit radiation exposure. 
Definitions
A complete set of definitions of terms used throughout the indication set is listed in Appendix A. These definitions were provided and discussed with the technical panel prior to ratings of indications. Ischemic Equivalent Chest Pain Syndrome, Anginal Equivalent, or Ischemic Electrocardiographic Abnormalities: Any constellation of clinical findings that is clinically judged to be consistent with obstructive CAD. Examples of such findings include, but are not limited to, chest pain, chest tightness, burning, shoulder pain, jaw pain, and new electrocardiographic abnormalities suggestive of ischemic heart disease. Nonchest pain symptoms, such as dyspnea or worsening effort tolerance that are felt to be consistent with CAD may also be considered to be an anginal equivalent.
Determining Pretest Risk Assessment for Risk Stratification Coronary Heart Disease (CHD) Risk in Asymptomatic
Patients: Estimation of CHD risk applied to asymptomatic patients without known CHD. It is assumed that clinicians will use CCT studies in addition to standard methods of risk assessment as presented in the National Heart, Lung, and Blood Institute report 10 on "Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III [ATP III])." Absolute risk is defined as the probability of developing CHD, including myocardial infarction or CHD death over a given time period. The ATP III report specifies absolute risk for CHD over the next 10 years. CHD risk refers to 10-year risk for any hard cardiac event. However, in acknowledgment that global absolute risk scores may be miscalibrated to certain populations (eg, women, younger men), clinical judgment must be applied in selecting categorical risk thresholds.
• CHD Risk-Low
Defined by the age-specific risk level that is below average. In general, low risk will correlate with a 10-year absolute CHD risk Ͻ10%.
• CHD Risk-Intermediate
Defined by the age-specific risk level that is average or above average. In general, moderate risk will correlate with a 10-year absolute CHD risk between 10% to 20%. Among women and younger men, an expanded intermediate risk range of 6% to 20% may be appropriate.
• CHD Risk-High
Defined as the presence of diabetes mellitus in a patient Ն40 years of age, peripheral arterial disease or other coronary risk equivalents, or the 10-year absolute CHD risk of Ͼ20%.
Pretest Probability of Obstructive/Significant CAD for Symptomatic (Ischemic Equivalent) Patients: Once the physician determines the presence of symptoms that may represent obstructive CAD (ischemic equivalent present), the pretest probability of CAD should be assessed. There are a number of risk algorithms 11, 12 available that can be used to calculate this probability. Clinicians should become familiar with those that pertain to the populations they encounter most often. In scoring the indications, the following probabilities as calculated from any of the various available algorithms should be applied:
• Low pretest probability: Ͻ10% pretest probability of CAD.
• Intermediate pretest probability: Between 10% and 90% pretest probability of CAD. • High pretest probability: Ͼ90% pretest probability of CAD.
The method recommended by the ACC/AHA Guidelines for Chronic Stable Angina 13 is provided in the following text as 1 example of a method used to calculate pretest probability and is a modification of a previously published literature review. 14 
Cardiac Computed Tomography Appropriate Use Criteria (By Indication)

Detection of CAD in Symptomatic Patients Without Known Heart Disease Symptomatic-Nonacute Symptoms Possibly Representing an Ischemic Equivalent 1.
• ECG interpretable AND • Able to exercise • Intermediate pretest probability of CAD A (7) 2.
• ECG uninterpretable or unable to exercise • Low pretest probability of CAD A (7) 2.
• ECG uninterpretable or unable to exercise • Intermediate pretest probability of CAD A (8)
Detection of CAD in Symptomatic Patients Without Known Heart Disease Symptomatic-Acute Symptoms With Suspicion of ACS (Urgent Presentation)
6.
• Normal ECG and cardiac biomarkers • Low pretest probability of CAD A (7)
6.
• Normal ECG and cardiac biomarkers • Intermediate pretest probability of CAD A (7) 7.
• ECG uninterpretable • Low pretest probability of CAD A (7) 7.
• ECG uninterpretable • Intermediate pretest probability of CAD A (7) 8.
• Nondiagnostic ECG or equivocal cardiac biomarkers • Low pretest probability of CAD A (7) 8.
• Nondiagnostic ECG or equivocal cardiac biomarkers • Intermediate pretest probability of CAD A (7)
Detection of CAD/Risk Assessment in Asymptomatic Individuals Without Known CAD-Noncontrast CT for CCS
9.
• Family history of premature CHD • Low global CHD risk estimate A (7) 10.
• Asymptomatic • No known CAD • Intermediate global CHD risk estimate A (7)
Detection of CAD in Other Clinical Scenarios-New-Onset or Newly Diagnosed Clinical HF and No Prior CAD
13.
• Reduced left ventricular ejection fraction • Low pretest probability of CAD A (7) 13.
• Reduced left ventricular ejection fraction • Intermediate pretest probability of CAD A (7)
Detection of CAD in Other Clinical Scenarios-Preoperative Coronary Assessment Prior to Noncoronary Cardiac Surgery
15.
• Coronary evaluation before noncoronary cardiac surgery • Intermediate pretest probability of CAD 
Risk Assessment Postrevascularization (PCI or CABG)-Asymptomatic-Prior Coronary Stenting
43.
• Prior left main coronary stent with stent diameter Ն3 mm A (7)
Evaluation of Cardiac Structure and Function-Adult Congenital Heart Disease
46.
• Assessment of anomalies of coronary arterial and other thoracic arteriovenous vessels A (9) 47.
• Assessment of complex adult congenital heart disease A (8) 
Evaluation of Cardiac Structure and Function-Evaluation of Ventricular Morphology and Systolic Function
Detection of CAD in Symptomatic Patients Without Known Heart Disease Symptomatic-Nonacute Symptoms Possibly Representing an Ischemic Equivalent 1.
• ECG interpretable and able to exercise • Low pretest probability of CAD U (5)
2.
• ECG uninterpretable or unable to exercise • High pretest probability of CAD U (4)
Detection of CAD in Symptomatic Patients Without Known Heart Disease Symptomatic-Acute Symptoms With Suspicion of ACS (Urgent Presentation)
4.
• Persistent ECG ST-segment elevation following exclusion of MI U (6)
5.
• Acute chest pain of uncertain cause (differential diagnosis includes pulmonary embolism, aortic dissection, and ACS ["triple rule out"]) U (6) 
Detection of CAD in Other Clinical Scenarios-Preoperative Coronary Assessment Prior to Noncoronary Cardiac Surgery
15.
• Coronary evaluation before noncoronary cardiac surgery • Low pretest probability of CAD U (6)
Detection of CAD in Other Clinical Scenarios-Arrhythmias-Etiology Unclear After Initial Evaluation
17.
• Nonsustained ventricular tachycardia U (6) 18.
• Syncope U (4)
Detection of CAD in Other Clinical Scenarios-Elevated Troponin of Uncertain Clinical Significance
19.
• Elevated troponin without additional evidence of ACS or symptoms suggestive of CAD U (6) 
Use of CTA in the Setting of Prior Test Results-Sequential Testing After Stress Imaging Procedures
Use of CTA in the Setting of Prior Test Results-Evaluation of New or Worsening Symptoms in the Setting of Past Stress Imaging Study
29.
• Previous stress imaging study abnormal U (6)
Risk Assessment Preoperative Evaluation of Noncardiac Surgery Without Active Cardiac Conditions-Intermediate-Risk Surgery
33.
• Functional capacity Ͻ4 METs with 1 or more clinical risk predictors U (5)
Risk Assessment Preoperative Evaluation of Noncardiac Surgery Without Active Cardiac Conditions-Vascular Surgery
37.
• Functional capacity Ͻ4 METs with 1 or more clinical risk predictors U (6)
Risk Assessment Postrevascularization (PCI or CABG)-Symptomatic (Ischemic Equivalent)
41.
• Prior coronary stent with stent diameter Ն3 mm U (6)
Risk Assessment Postrevascularization (PCI or CABG)-Asymptomatic-CABG
42.
• Prior coronary bypass surgery Ն5 y ago U (5)
Risk Assessment Postrevascularization (PCI or CABG)-Asymptomatic-Prior Coronary Stenting
44.
• Stent diameter Ն3 mm • Greater than or equal to 2 y after PCI U (4)
Evaluation of Cardiac Structure and Function-Evaluation of Ventricular Morphology and Systolic Function
52.
• Assessment of myocardial viability prior to myocardial revascularization 
Detection of CAD in Symptomatic Patients Without Known Heart Disease Symptomatic-Nonacute Symptoms Possibly Representing an Ischemic Equivalent 1.
• ECG interpretable and able to exercise • High pretest probability of CAD
I (3)
Detection of CAD in Symptomatic Patients Without Known Heart Disease Symptomatic-Acute Symptoms With Suspicion of ACS (Urgent Presentation)
3.
• Definite MI I (1)
Detection of CAD/Risk Assessment in Asymptomatic Individuals Without Known CAD-Noncontrast CT for CCS
10.
• Low global CHD risk estimate I (2)
Detection of CAD/Risk Assessment in Asymptomatic Individuals Without Known CAD-Coronary CTA
11.
• Low global CHD risk estimate I (2) 11.
• Intermediate global CHD risk estimate I (2)
Detection of CAD in Other Clinical Scenarios-Preoperative Coronary Assessment Prior to Noncoronary Cardiac Surgery
15.
• Coronary evaluation before noncoronary cardiac surgery • High global CHD risk estimate
Detection of CAD in Other Clinical Scenarios-Arrhythmias-Etiology Unclear After Initial Evaluation
16.
• New-onset atrial fibrillation (atrial fibrillation is underlying rhythm during imaging) I (2) 
Use of CTA in the Setting of Prior Test Results-ECG Exercise Testing
Risk Assessment Postrevascularization (PCI or CABG)-Symptomatic (Ischemic Equivalent)
40.
• Prior coronary stent with stent diameter Ͻ3 mm or not known I (3)
Risk Assessment Postrevascularization (PCI or CABG)-Asymptomatic-CABG
42.
• Prior coronary bypass surgery Ͻ5 y ago I (2) 
Discussion
Appropriate use criteria define common patient subgroups where expert opinion and the available medical evidence are combined to assess the net benefit of a test or procedure, in this instance CCT. The intent of these criteria is to guide the rational use of the procedure, namely avoidance of either under-or overutilization, and thereby lead to more optimal healthcare delivery and justifiable healthcare expenditures. This document is an update to the original appropriateness criteria for CCT published in 2006, 1 written to reflect changes in test utilization in the context of rapidly developing technical and clinical applications and within the conceptual framework of dynamic appropriate use criteria development. Several aspects of the present document are noteworthy, including careful alignment to and, where possible, definition of language in the radionuclide imaging appropriate use criteria 2 to enhance integration into comparable decision support tools and performance metrics. The underlying assumptions for the document are intended to broadly reflect the present community standards of technology and performance of the technique with an emphasis on adherence to imaging guidelines, patient safety, and laboratory quality and accreditation.
The clinical scenarios included in this report were designed to reflect the most common and important potential applications for CCT imaging. After the initial writing by the writing group, extensive review from external editors, and then ranking by the technical panel itself, the result is a set of scenarios that define patient-specific applications. The appropriate use criteria in this report provide a consensus judgment of whether it is reasonable to use CCT imaging for the particular clinical scenario described, such as those 93 indications listed in this document. These criteria are expected to be useful for clinicians, healthcare facilities, and third-party payers engaged in the delivery of cardiovascular imaging services. Although numerous, the indications are commonly divided among subclasses of patient CHD risk or pretest probability of CAD, as such characteristics are important considerations within the test performance characteristics. In total, 35 of 93 indications were judged to be appropriate, and 58 were judged to be either inappropriate or uncertain. It is important to note however, that an understanding of pretest patient characteristics is an important determinant of the appropriate use ratings. Few categories are uniform in the ratings for all patient characteristics.
Appropriate use criteria represent the first component of the chain of quality recommendations for cardiovascular imaging. 15 In addition to appropriate use, patient safety also should be considered when ordering coronary computed tomographic angiography (CTA), as it should be when ordering any cardiac imaging test. A consideration of the appropriate balance of using radiation dose reduction techniques to minimize radiation exposure while preserving image quality and the related benefits of imaging for a specific patient should be undertaken. This issue is discussed in more depth in a 2010 expert consensus document on coronary CTA. 16 The present document greatly expands the number of potential clinical scenarios in comparison to the original 2006 document. The clinical scenarios include acute and chronic chest pain, testing in symptomatic and asymptomatic patients, heart failure, preoperative risk assessment before both cardiac and noncardiac surgery, testing in the setting of prior test results (exercise testing, stress imaging procedures, coronary calcium scores, and repeat testing), prior revascularization, and the evaluation of cardiac structure and function. Although these criteria are intended to provide guidance for patients and clinicians, they are not intended to serve as substitutes for sound clinical judgment and practice experience. The writing group recognizes that many patients Additionally, uncertain indications often require individual physician judgment and understanding of the patient to better determine the usefulness of a test for a particular scenario. As such, the ranking of an indication as uncertain (4 to 6) should not be viewed as limiting the use of CCT imaging for such patients. It should be emphasized that the technical panel was instructed that the uncertain designation was still designed to be considered as a "reimbursable" category. These ratings are intended to evaluate the appropriate use of specific patient scenarios to determine overall patterns of care regarding CCT. In situations where there is substantial variation between the appropriate use rating and what the clinician believes is the best recommendation for the patient, further considerations or actions, such as a second opinion, may be appropriate. Moreover, it is not anticipated that all physicians or facilities will have 100% of their CCT procedures deemed appropriate. However, related to the overall patterns of care, if the national average of appropriate and uncertain ratings is 80%, for example, and a physician or facility has a 40% rate of inappropriate procedures, further examination of the patterns of care may be warranted and helpful. Implementation of these criteria is highly encouraged through provider education, as it is anticipated that increasing emphasis by laboratory accreditation bodies and other organizations focused on provider quality will apply.
Clinical Scenarios and Their Ratings
Direct comparison to the 2006 document is difficult because of the many changes in the number and wording of clinical scenarios. In summary:
• A total of 31 indications were carried forward from the 2006 document, including prior ratings where 10 were appropriate, 10 were uncertain, and 11 were inappropriate. Among these, • The use of CCT was appropriate prior to electrophysiological procedures for anatomic mapping, or prior to repeat sternotomy in reoperative cardiac surgery. • There was disagreement on the panel in 2 of the clinical scenarios: 1) detection of CAD in the setting of a low pretest probability for CAD when the ECG is interpretable and the patient is able to exercise (Indication 1); and 2) preoperative coronary assessment prior to noncoronary cardiac surgery in the setting of a low pretest probability for CAD (Indication 30). Both of these indications were ranked in the uncertain category.
Application of Criteria
There are many potential applications for appropriate use criteria. Clinicians could use the ratings for decision support or an educational tool when considering the need for CCT imaging. Moreover, these criteria could be used to facilitate discussion with patients and/or referring physicians about the need for CCT imaging. Facilities and payers may choose to use these criteria either prospectively in the design of protocols and preauthorization procedures, or retrospectively for quality reports. It is hoped that payers would use these criteria as the basis for the development of rational payment management strategies. These criteria were developed with the intent that they be considered in both the delivery and in the policy positions for these services, including reimbursement. In contrast, services performed for inappropriate indications should likely require additional documentation to justify reimbursement because of the unique circumstances or the clinical profile that must exist in such a patient. It is critical to emphasize that the writing group, technical panel, Appropriate Use Criteria Task Force, and clinical community do not believe an uncertain rating is grounds to deny reimbursement for CCT imaging. Rather, uncertain ratings are those where expert opinion or the available data vary or are rapidly evolving. The opinions of the technical panel often varied for these indications reflecting that additional research is needed. By the same right, appropriate indications may still benefit from further clinical trials and evidence development.
In conclusion, this document represents the current understanding of the net clinical benefit of CCT imaging with respect to the balance between benefit and risk to the patient as assessed under the ACCF's appropriate use criteria meth-odology. It is intended to provide a practical guide and perspective to clinicians and patients when considering CCT imaging and promote more appropriate test utilization including avoidance of either under-or overutilization. As with other appropriate use criteria, some of these ratings will require research and further evaluation to provide the greatest information and benefit to clinical decision making. Finally, it will be necessary to periodically assess and update the indications and criteria as technology evolves and new data and field experience become available.
Appendix A: Additional Cardiac Computed Tomography Definitions
Angina: As defined by the ACC/AHA Guidelines on Exercise Testing 9
• Typical Angina (Definite): 1. Substernal chest pain, or an ischemic equivalent discomfort that is a. provoked by exertion or emotional stress and b. relieved by rest and/or nitroglycerin. 17 • Atypical Angina (Probable): Chest pain or discomfort with two characteristics of definite or typical angina. 17 Figure A1 . Stepwise Approach to Perioperative Cardiac Assessment. Cardiac evaluation and care algorithm for noncardiac surgery based on active clinical conditions, known cardiovascular disease, or cardiac risk factors for patients Ն50 years of age. HR indicates heart rate; LOE, level of evidence; and MET, metabolic equivalent. Modified from Fleisher et al. 19 • Nonanginal Chest Pain: Chest pain or discomfort that meets one or none of the typical angina characteristics. 17
Acute Coronary Syndrome: As defined by the ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, patients with an acute coronary syndrome include those whose clinical presentations cover the following range of diagnoses: unstable angina, MI without ST-elevation (NSTEMI), and myocardial infarction with ST-elevation (STEMI). 18
Evaluating Perioperative Risk for Noncardiac Surgery
METHOD FOR DETERMINING PERIOPERATIVE RISK
Review Figure A1 , "Stepwise Approach to Perioperative Cardiac Assessment," from the ACC/AHA 2009 Perioperative Guidelines. 19 Based on the algorithm, once it is determined that the patient does not require urgent surgery, the clinician should determine the patient's active cardiac conditions and/or perioperative risk predictors-see definitions in the following text. If any active cardiac conditions (Table A1) and/or major risk predictors (Table A2 ) are present, Figure A1 suggests consideration of coronary angiography and postponing or canceling noncardiac surgery. Once perioperative risk predictors are assessed based on the algorithm, then the surgical risk and patient's functional status should be used to establish the need for noninvasive testing.
ECG-Uninterpretable:
Refers to electrocardiograms with resting ST-segment depression (Ն0.10 mV), complete left bundle-branch block, pre-excitation (Wolff-Parkinson-White syndrome), or paced rhythm.
Able to Exercise: Able to complete a diagnostic exercise treadmill examination.
Appendix B: Additional Methods
See the Methods section for a description of panel selection, indication development, scope of indications, and rating process.
Relationships With Industry and Other Entities
A list of all individuals participating in the development and review of this document and their institutional and/or organizational affiliations is presented in Appendix C. ACCF and its partnering organizations rigorously avoid any actual, perceived, or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the technical panel. Specifically, all panel members are asked to provide disclosure statements of all relationships that might be perceived as real or potential conflicts of interest. These statements were reviewed by the Appropriate Use Criteria Task Force, discussed with all members of the technical panel at the face-to-face meeting, and updated and reviewed as necessary. A table of disclosures by the technical panel and oversight task force members can be found in Appendix D.
Literature Review
The technical panel members were asked to refer to the relevant literature provided for each indication table when completing their ratings (Online Appendix at http:// circ.ahajournals.org/cgi/reprint/CIR.0B013e3181fcae66).
Appendix C: ACCF/SCCT/ACR/AHA/ASE/ ASNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography Participants Cardiac Computed Tomography Writing Group
Allen J. Taylor, MD, FACC, FAHA-Chair, Appropriate Use Criteria for Cardiac Computed Tomography Writing Group, Co-Director Noninvasive Imaging, Washington Hospital Center, Washington, DC Manuel Cerqueira, MD, FACC, FASNC-Chairman of Molecular and Functional Imaging, Cleveland Clinic Foundation, Cleveland, OH 19 CCS indicates Canadian Cardiovascular Society; HF, heart failure; HR, heart rate; MI, myocardial infarction; and NYHA, New York Heart Association. *As defined by the ACCF/AHA guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. 1 Note that these are not standard coronary artery disease risk factors.
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